Shares of Catalent, Inc. (NYSE:CTLT – Get Rating) gapped up before the market opened on Friday . The stock had previously closed at $32.14, but opened at $35.07. Catalent shares last traded at $37.08, with a volume of 5,292,248 shares changing hands.
Analyst Ratings Changes
CTLT has been the subject of several analyst reports. William Blair downgraded Catalent from an “outperform” rating to a “market perform” rating in a research report on Friday, April 14th. Barclays decreased their target price on Catalent from $70.00 to $40.00 in a research report on Monday, April 17th. Royal Bank of Canada decreased their target price on Catalent from $58.00 to $41.00 in a research report on Monday, May 8th. StockNews.com assumed coverage on Catalent in a report on Thursday. They issued a “sell” rating for the company. Finally, Deutsche Bank Aktiengesellschaft downgraded Catalent from a “buy” rating to a “hold” rating and reduced their price target for the company from $55.00 to $29.00 in a report on Monday, May 15th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $74.80.
Catalent Price Performance
The company has a 50 day simple moving average of $53.08 and a 200-day simple moving average of $53.03. The stock has a market cap of $6.69 billion, a price-to-earnings ratio of 16.45, a PEG ratio of 3.97 and a beta of 1.17. The company has a quick ratio of 1.38, a current ratio of 1.91 and a debt-to-equity ratio of 0.86.
Insider Transactions at Catalent
Hedge Funds Weigh In On Catalent
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Chevy Chase Trust Holdings LLC boosted its stake in Catalent by 0.7% during the 1st quarter. Chevy Chase Trust Holdings LLC now owns 104,654 shares of the company’s stock valued at $6,877,000 after purchasing an additional 713 shares in the last quarter. KB Financial Partners LLC bought a new position in Catalent during the 1st quarter valued at $30,000. Mercer Global Advisors Inc. ADV boosted its stake in Catalent by 18.7% during the 1st quarter. Mercer Global Advisors Inc. ADV now owns 44,900 shares of the company’s stock valued at $2,950,000 after purchasing an additional 7,081 shares in the last quarter. Hudson Bay Capital Management LP bought a new position in Catalent during the 1st quarter valued at $13,757,000. Finally, Snyder Capital Management L P boosted its stake in Catalent by 0.7% during the 1st quarter. Snyder Capital Management L P now owns 1,169,232 shares of the company’s stock valued at $76,830,000 after purchasing an additional 7,940 shares in the last quarter. 99.38% of the stock is owned by institutional investors.
Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.